T&R Biofab Signs Joint Research Agreement for 3D Biotissue Scaffold Development

[Asia Economy Reporter Jang Hyowon] T&R Biofab (CEO Yoon Wonsoo) announced on the 5th that it has signed a strategic joint research agreement with Ethicon, a subsidiary of Johnson & Johnson's medical device division, to develop 3D bio-printed soft tissue scaffold products using 3D bioprinting technology.

This collaboration aims to develop innovative soft tissue regeneration and repair products differentiated from existing products, based on T&R Biofab's strengths in polymers, ECM (Extra Cellular Matrix), and 3D bioprinting platform technology. Ethicon will have an exclusive option (right of first negotiation) to commercialize the 3D bioprinting technology derived from the joint research.

The contract signing was led by Johnson & Johnson Innovation Asia Pacific Headquarters, and the joint research execution will be managed by the global Johnson & Johnson 3D Printing Center.

The products using 3D bioprinting technology can be applied in various fields such as wound suturing, wound treatment patches, hernia treatment, soft tissue regeneration during tendon reconstructive plastic surgery or reconstructive surgery, fascia reconstruction, and soft tissue regeneration.

Yoon Wonsoo, CEO of T&R Biofab, stated, “Through this joint development contract with Ethicon, we aim to further strengthen technological innovation and secure momentum for growth into the global business.”

Meanwhile, T&R Biofab, established in 2013 as a bio-venture company, is developing and commercializing biodegradable medical devices, bioinks, organoids (mini artificial organs), and 3D printed cell therapies by utilizing 3D printing technology, a key innovative technology of the 4th Industrial Revolution.

This content was produced with the assistance of AI translation services.